Company
Headquarters: London, United Kingdom
Employees: 5
CEO: Mr. Nigel James Theobald
£4.4 Million
GBP as of Jan. 1, 2026
US$5.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. The company has a research collaboration with Nanomerics Limited to focus on the different formulations of Nuvec delivery system. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £1,953 |
| EBITDA | £0 |
| Gross Profit TTM | £0 |
| Profit Margin | 0.00% |
| Operating Margin | -35338.49% |
| Quarterly Revenue Growth | % |
N4 Pharma plc has the following listings and related stock indices.
Stock: LSE: N4P